Proteoglycans and their roles in brain cancer. (6th February 2013)

• Record Type: Journal Article
• Authors: Wade, Anna; Robinson, Aaron E.; Engler, Jane R.; Petritsch, Claudia; James, C. David; Phillips, Joanna J.
• Is Part Of: FEBS journal. Volume 280:Number 10(2013)
• Page Start: 2399
• Page End: 2417
• Publication Date: 2013-02-06
• Subjects: CSPG -- GBM -- GPC1 -- HSPG -- NG2 -- proteoglycans -- SULF -- sulfatase -- tumor microenvironment; Biochemistry -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 572
• DOI: 10.1111/febs.12109
• Languages: English
• ISSNs: 1742-464X

Abstract

Abstract : Glioblastoma, a malignant brain cancer, is characterized by abnormal activation of receptor tyrosine kinase signalling pathways and a poor prognosis. Extracellular proteoglycans, including heparan sulfate and chondroitin sulfate, play critical roles in the regulation of cell signalling and migration via interactions with extracellular ligands, growth factor receptors and extracellular matrix components, as well as intracellular enzymes and structural proteins. In cancer, proteoglycans help drive multiple oncogenic pathways in tumour cells and promote critical tumour–microenvironment interactions. In the present review, we summarize the evidence for proteoglycan function in gliomagenesis and examine the expression of proteoglycans and their modifying enzymes in human glioblastoma using data obtained from The Cancer Genome Atlas (http://cancergenome.nih.gov/). Furthermore, we demonstrate an association between specific proteoglycan alterations and changes in receptor tyrosine kinases. Based on these data, we propose a model in which proteoglycans and their modifying enzymes promote receptor tyrosine kinase signalling and progression in glioblastoma, and we suggest that cancer‐associated proteoglycans are promising biomarkers for disease and therapeutic targets. Abstract : Glioblastoma (GBM) is characterized by abnormal activation of receptor tyrosine kinase signaling pathways and a poor prognosis. In cancer, extracellular proteoglycans help regulate oncogenic signaling and tumor cell invasion via extracellular interactions with ligands, receptors, and extracellular matrix components, and intracellular interactions with enzymes and structural proteins. We propose that proteoglycan alterations promote GBM progression and represent promising therapeutic targets.